摘要
目的:观察左乙拉西坦与托吡酯治疗原发性癫痫的疗效及安全性,并探讨其对患儿免疫功能的影响。方法:选择我院2013年3月至2015年6月收治的原发性癫痫患儿60例,随机分为左乙拉西坦组和托吡酯组各30例,另选同期体检的健康儿童30例作为对照组。三组儿童均采集晨起空腹静脉血(患儿分别于治疗前和治疗3个月时各采集1次),采用免疫比浊法检测血清免疫球蛋白IgG、IgA、IgM水平,采用流式细胞技术检测T淋巴细胞亚群CD3^+、CD4^+、CD8^+水平。观察治疗前后各组患儿免疫功能指标变化、临床疗效及不良反应。结果:治疗前两组患儿IgA、IgG、IgM、CD3^+、CD4^+及CD8^+水平与对照组比较,差异均有统计学意义(P均<0.05);治疗后两组患儿IgA、IgG、CD8^+和(或)CD4^+水平较治疗前明显改善(P均<0.05),且与对照组比较差异无统计学意义(P均>0.05),两组患儿之间比较差异也无统计学意义(P均>0.05)。治疗3个月后,左乙拉西坦组总有效率为93.33%,托吡酯组为86.67%,两组比较差异无统计学意义(P>0.05)。两组患儿治疗过程中均无明显电解质紊乱、血尿常规及肝肾功能检查异常,不良反应轻微,无停药病例。结论:癫痫患儿存在免疫功能异常,应用左乙拉西坦和托吡酯均能改善其免疫功能,且二者疗效相当,安全性较高,均具有较高的临床应用价值。
Objective：To investigate the efficacy and safety of levetiracetam and topiramate on children with primary epilepsy,and investigate the effect on immune function.Methods：Sixty children with primary epilepsy from March 2013 to June 2015 were divided into levetiracetam group and topiramate group randomly,thirty cases in each group,and 30 cases of healthy children were selected as control group during the same period.All children were collected morning limosis venous blood,and the two groups of unhealthy children were collected blood both before and after 3 months＇ treatment,while the healthy children were collected blood only one time.The levels of lg G,IgA and IgM were detected by immune turbidimetry,and CD3~＋,CD4~＋ and CD8~＋ were detected by flow cytometry instrument.The immune function related indicators,curative effect and adverse reactions of groups were compared.Results：The levels of IgA,IgG,IgM,CD3~＋,CD4~＋ and CD8~＋ in the two groups of unhealthy children were significantly different from those of the control group（P〈0.05）.After treatment,IgA,IgG,CD8~＋ and（or） CD4＋in the two groups of unhealthy children were significantly improved than before treatment（P〈0.05）,and were not significantly different compared with the control group（P〈0.05）,and there were no significantly difference between the two groups of unhealthy children（P〈0.05）.Effective rate in the levetiracetam group was 93.33%,and in topiramate group was 86.67%,there was no significant difference between the two groups（P〉0.05）.The two groups of unhealthy children had no cases with obviously abnormal electrolyte disorder,blood and urine routine abnormalities,liver and kidney functions abnormalities,and adverse reactions were mild,and no withdrawal cases in two groups.Conclusion：Children with primary epilepsy have complicate abnormal immune function,both levetiracetam and topiramate can improve immune function to a certain extent,and also have therapeutic equivalence and high safety,which have high value in clinical application.
出处
《儿科药学杂志》
CAS
2017年第9期17-19,共3页
Journal of Pediatric Pharmacy
